ISB 2005
Alternative Names: ISB-2005Latest Information Update: 07 Sep 2022
At a glance
- Originator Ichnos Sciences
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 07 Sep 2022 Early research in Solid tumours in USA (Parenteral) (Ichnos Sciences pipeline, September 2022)
- 20 Apr 2022 ISB 2005 is available for licensing as of 20 Apr 2022. https://www.ichnossciences.com
- 20 Apr 2022 Early research in Haematological malignancies in USA (Parenteral) before April 2022 (Ichnos Sciences pipeline, April 2022)